Contraindications of sparsentan (sparsentan) and which groups should take it with caution

Sparsentan is a dual receptor antagonist that can simultaneously block angiotensin II receptor 1 type (AT1) and endothelin A span>Receptor (ETA) is mainly used to treat proteinuria nephropathy such asIgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS). As a new type of targeted drug, it has shown obvious clinical effects in improving renal function and reducing urinary protein levels. However, the use of sparsentane also carries certain risks, and not all patients are suitable for use. Understanding its contraindications and those who need to take it with caution is crucial to ensuring efficacy and safety.

1. Main contraindications for sparsentan

First of all, pregnant women are an absolute contraindication for this drug. Since sparsentan can affect fetal development, and may especially cause fetal renal dysfunction, oligohydramnios, and skeletal deformities, pregnant women and women planning pregnancy must strictly avoid pregnancy while taking it, and should take reliable contraceptive measures. Secondly, people who are allergic to drug ingredients are prohibited from using it. If the patient has had an allergic reaction to angiotensin II receptor blockers (such as valsartan, losartan) or endothelin receptor antagonists (such as bosentan), sparsentan should be avoided. In addition, this drug is contraindicated in patients with severe hepatic insufficiency (Child-Pugh C grade) because it is mainly metabolized by the liver, and liver dysfunction may lead to drug accumulation and serious adverse reactions.

2. Special groups of people who need to use it with caution

For patients with mild to moderate hepatic impairment, caution should be used and the dose should be adjusted, while liver function indicators should be closely monitored. Patients with renal insufficiency, especially those undergoing dialysis, also need to take it with caution because blood concentration may increase, increasing the risk of side effects. Patients with low blood pressure or taking antihypertensive drugs should pay special attention when taking it. Sparsentane may further lower blood pressure, causing dizziness, fatigue and other discomforts. In addition, elderly patients have weaker metabolic abilities and should start with a low dose and gradually adjust. Because sparsentan may cause an increase in blood potassium (hyperkalemia), patients taking concomitant potassium-sparing diuretics, ACE inhibitors, or ARBs should carefully monitor their potassium levels to avoid the risk of arrhythmias.

3. Monitoring and safety management during medication

During sparsentan treatment, liver function (ALT, AST should be monitored regularly), renal function (creatinine, urea nitrogen) and blood potassium levels, especially in the early stages of treatment or when combined with drugs, need to be closely observed. If the patient develops signs of liver damage such as jaundice, obvious fatigue, decreased appetite, or darker urine, the drug should be discontinued immediately and seek medical attention. For low blood pressure or discomfort such as dizziness and nausea, the dose can be appropriately reduced or the medication time can be adjusted. Patients should avoid concurrent use with strong CYP3A inhibitors (such as ketoconazole) or inducers (such as rifampicin) to prevent abnormal increases or decreases in drug blood concentrations, affecting efficacy and safety.

4. Special reminder for women and patients of childbearing age

Due to the potential teratogenicity of sparsentane, women should have a pregnancy test before taking the drug and use effective contraception during treatment and for at least one month after stopping the drug. It is also not recommended for breastfeeding women to use this drug because it is not clear whether the drug is excreted through breast milk and may have adverse effects on the baby. In addition, if patients plan to become pregnant or breast-feeding, they should communicate with their doctor in advance and consider other safer alternative treatments.

Overall, sparsentane is effective in treating proteinuric kidney diseases such as IgA nephropathy, but it is not suitable for all patients. Pregnant women, those with severe hepatic insufficiency and those with drug allergies should be banned. Patients with renal dysfunction, the elderly and those taking antihypertensive drugs or potassium-sparing drugs should be cautious. Strictly complying with doctor's instructions and regularly monitoring relevant indicators are the keys to ensuring the safety and efficacy of medication.

Reference materials:https://www.drugs.com/